Development asset linked to Cumberland Pharmaceuticals in public FDA and regional records.
pharma · Pain · Hyponatremia · CPIX
Cumberland Pharmaceuticals
CUMBERLAND PHARMACEUTICALS INC
Cumberland Pharmaceuticals drug portfolio — 26 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
1600 W End Ave, #1300, Nashville, Tennessee 37203, US HQ
1999 Founded
128 Employees
Public company Type
CPIX · NYSE Ticker
Company details
- Status
- Public
- HQ
- 1600 W End Ave, #1300, Nashville, Tennessee 37203, US
- Founded
- 1999
- Employees
- 128
- Programs
- 53
- Drugs
- 26
- Patents
- 34
Cumberland Pharmaceuticals pipeline
Portfolio lens on 26 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Cumberland Pharmaceuticals drug portfolio — 26 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
US regulatory status: approved. Molecular target: Fatty-acid amide hydrolase 1.
- Target
- Fatty-acid amide hydrolase 1
- Mechanism
- Cyclooxygenase inhibitor
-
US regulatory status: approved.
-
US regulatory status: approved. Mechanism: Glutathione precursor.
- Mechanism
- Glutathione precursor
-
US regulatory status: approved. Molecular target: Cyclooxygenase.
- Target
- Cyclooxygenase
- Mechanism
- Cyclooxygenase inhibitor
-
Development asset linked to Cumberland Pharmaceuticals in public FDA and regional records. Mechanism: HMG-CoA reductase inhibitor.
- Mechanism
- HMG-CoA reductase inhibitor
-
Development asset linked to Cumberland Pharmaceuticals in public FDA and regional records.
-
Development asset linked to Cumberland Pharmaceuticals in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Vasopressin V1a receptor.
- Target
- Vasopressin V1a receptor
- Mechanism
- Vasopressin V1a receptor antagonist
-
Development asset linked to Cumberland Pharmaceuticals in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Tubulin.
- Target
- Tubulin
- Mechanism
- Tubulin inhibitor
-
ibuprofen
Cardiovascular system (C01)US regulatory status: approved. Molecular target: Cyclooxygenase.
- Target
- Cyclooxygenase
- Mechanism
- Cyclooxygenase inhibitor
-
Development asset linked to Cumberland Pharmaceuticals in public FDA and regional records.
-
Development asset linked to Cumberland Pharmaceuticals in public FDA and regional records.
-
US regulatory status: approved. Mechanism: Colonic bacteria substrate.
- Mechanism
- Colonic bacteria substrate
-
Development asset linked to Cumberland Pharmaceuticals in public FDA and regional records.
-
Development asset linked to Cumberland Pharmaceuticals in public FDA and regional records.
-
Development asset linked to Cumberland Pharmaceuticals in public FDA and regional records.
-
Development asset linked to Cumberland Pharmaceuticals in public FDA and regional records.
-
Development asset linked to Cumberland Pharmaceuticals in public FDA and regional records.
-
ranibizumab
Sensory organs (S01)US regulatory status: approved. Molecular target: Vascular endothelial growth factor A, long form.
- Target
- Vascular endothelial growth factor A, long form
- Mechanism
- Vascular endothelial growth factor A inhibitor
-
Development asset linked to Cumberland Pharmaceuticals in public FDA and regional records.
-
Development asset linked to Cumberland Pharmaceuticals in public FDA and regional records.
-
telavancin
Antiinfectives for systemic use (J01)US regulatory status: approved.
-
US regulatory status: approved. Molecular target: Cell outer membrane.
- Target
- Cell outer membrane
- Mechanism
- Cell outer membrane inhibitor
-
US regulatory status: approved. Mechanism: Diagnostic agent.
- Mechanism
- Diagnostic agent